Allele Biotech and Pharmaceuticals (AKA: Allele Biotechnology and Pharmaceuticals) Profile last edited on: 2/20/19
CAGE: 4TUH4
UEI:
Business Identifier: Biomedical research and therapy development 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
6404 Nancy Ridge Drive
San Diego, CA 92121
San Diego, CA 92121
| (858) 587-6645 |
| oligo@allelebiotech.com |
| www.allelebiotech.com |
Location: Single
Congr. District: 52
County: San Diego
Congr. District: 52
County: San Diego
Public Profile
Allele Biotechnology and Pharmaceuticals, Inc. explores the mechanisms of biological processes to develop technologies and products for biomedical researchers. Founded by scientists and other professionals having the mission of increasing accessibility to innovative molecular biology research tools, the firmhas become a reliable source for a wide variety of Molecular Biology reagents, superior fluorescent proteins, camelid derived nano antibodies (nAb), cellular reprogramming services and reagents, and immundiagnostic kits and various other products and custom services. A hallmark of the firm is offering cutting edge products at a reasonable cost. Further, having the technical knowledge needed to facilitate their use, Allele personnel are available to answer questions regarding any of the firm's products.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1.5M-2MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2018 | 1 | NIH | $225,001 | |
| Project Title: Effective Nanoantibodies as Promising Therapeutics for Treating Sepsis | ||||
| 2017 | 1 | NIH | $225,000 | |
| Project Title: Human Neural Stem Cells Engineered against oA?Induced Toxicity for Cell Therapy | ||||
| 2016 | 1 | NIH | $222,173 | |
| Project Title: Adaptable and Automated Large-Scale Manufacturing of Ipsc-Derived Cell Products | ||||
| 2016 | 1 | NIH | $225,000 | |
| Project Title: Anti-RPS23RG1 Nanoantibody as Novel Therapeutic and Research Reagents for Alzheimers Disease | ||||
| 2015 | 1 | NIH | $224,999 | |
| Project Title: Generation and Characterization of Nanobodies Against Beta-Amyloid | ||||
Key People / Management
Jiwu Wang -- President and CEO
Haixia Gong
Wang Jiwu
Chelsea Sykora -- Lead Research Associate
Shichun Tu
Anthony Wong -- Director of Investigative Pathology
Haixia Gong
Wang Jiwu
Chelsea Sykora -- Lead Research Associate
Shichun Tu
Anthony Wong -- Director of Investigative Pathology
